Vigabatrin Ph 1 Cocaine Interaction Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00626834|
Recruitment Status : Completed
First Posted : February 29, 2008
Last Update Posted : January 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Cocaine Addiction||Drug: Vigabatrin Drug: Matching placebo||Phase 1|
STUDY DESIGN: This is a randomized, double-blind, placebo-controlled, parallel group study of the effects of VGB compared to placebo control on the physiological and subjective effects of IV infusions of cocaine (cocaine experienced volunteers).
Subjects will be randomized within each clinical site to one of four groups (placebo control or one of three doses of VGB twice daily).During VGB steady state dosing, subjects will receive double-blind infusions of saline and cocaine. Subjects will be asked to return for follow-up approximately 7 and 14 days after the day of clinic discharge.
STUDY DURATION: The maximum duration is 56 days, including 14 inpatient days of assessments and investigational products administration, and two follow-up visits after clinic discharge.
SAMPLE SIZE: Twenty-four subjects will be randomized to one of three doses of vigabatrin or placebo.
POPULATION: Volunteer, cocaine-experienced, non-treatment seeking cocaine users, 18 to 45 years of age.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Intravenous Cocaine and Oral Gamma Vinyl-Gamma-Amino Butyric Acid (VIGABATRIN) Interaction Study|
|Study Start Date :||February 2008|
|Primary Completion Date :||October 2010|
|Study Completion Date :||October 2010|
|Experimental: Vigabatrin Dose 1||
Dose 1 BID
|Experimental: Vigabatrin Dose 2||
Dose 2 BID
|Experimental: Vigabatrin Dose 3||
Dose 3 BID
|Placebo Comparator: Matching placebo||
Drug: Matching placebo
Matching placebo BID
- safety/tolerability and AE assessments including HR/BP/ECG/QTc [ Time Frame: 56 days ]
- VGB/PK during cocaine infusions and effect of VGB on cocaine craving [ Time Frame: 28 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00626834
|United States, Texas|
|University of Texas Health Science Center|
|San Antonio, Texas, United States, 78229|
|Principal Investigator:||John D. Roache, Ph.D.||University of Texas|
|Principal Investigator:||Nora Chiang, Ph.D.||National Institute on Drug Abuse (NIDA)|
|Principal Investigator:||Ahmed Elkashef, M.D.||National Institute on Drug Abuse (NIDA)|
|Principal Investigator:||Roberta Kahn, M.D.||National Institute on Drug Abuse (NIDA)|